Bacillus coagulans TBC169 probiotics for intestinal function recovery after gynecological open surgery: a randomized, double-blind, placebo-controlled trial.
{"title":"Bacillus coagulans TBC169 probiotics for intestinal function recovery after gynecological open surgery: a randomized, double-blind, placebo-controlled trial.","authors":"Zhaobo Guan, Zhijiao Zhang, Pengyan Jia, Juan Xu, Niuniu Bai, Chunxia Hou, Weihong Chen, Weiqi Gao","doi":"10.1007/s11096-025-01881-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Restoration of intestinal function after open surgery remains a significant challenge in gynecological practice. Bacillus coagulans TBC169 probiotics may enhance intestinal motility and recovery.</p><p><strong>Aim: </strong>This randomized controlled trial aimed to evaluate the efficacy and safety of Bacillus coagulans TBC169 in promoting intestinal function recovery after gynecological open abdominal surgery.</p><p><strong>Method: </strong>Patients undergoing open surgery were randomly assigned to high-dose (HDG), conventional-dose (CDG), or placebo-controlled (PCG) groups. The primary outcome was the time to first flatus (TFF). Secondary outcomes included time to first defecation (TFD), time to first bowel sounds (TFBS), duration of hospital stay (DHS), and postoperative complication rate (PCR).</p><p><strong>Results: </strong>A total of 114 patients were included, with 38 patients allocated to each group. TFF was significantly shorter in the CDG (25.8 h vs. 38.1 h, P < 0.001) and the HDG (23.1 h vs. 38.1 h, P < 0.001) than the PCG. TFBS was significantly reduced in the CDG (16.1 h vs. 19.3 h, P < 0.05) and the HDG (14.3 h vs. 19.3 h, P < 0.001). Patients in the HDG had a significantly shorter TFD than the PCG (61.2 h vs. 66.4 h, P < 0.05). However, DHS did not differ significantly among the groups. PCR was markedly lower in the CDG (34.2% vs. 68.4%, P < 0.01) and HDG (21.1% vs. 68.4%, P < 0.001) compared to the PCG. No adverse events were reported across the groups.</p><p><strong>Conclusion: </strong>Bacillus coagulans TBC169 accelerates intestinal function recovery and reduces postoperative complications following gynecologic open surgery.</p><p><strong>Trial registration: </strong>The study protocol was registered with the China Clinical Trials Registry (ChiCTR2200059518).</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-025-01881-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Restoration of intestinal function after open surgery remains a significant challenge in gynecological practice. Bacillus coagulans TBC169 probiotics may enhance intestinal motility and recovery.
Aim: This randomized controlled trial aimed to evaluate the efficacy and safety of Bacillus coagulans TBC169 in promoting intestinal function recovery after gynecological open abdominal surgery.
Method: Patients undergoing open surgery were randomly assigned to high-dose (HDG), conventional-dose (CDG), or placebo-controlled (PCG) groups. The primary outcome was the time to first flatus (TFF). Secondary outcomes included time to first defecation (TFD), time to first bowel sounds (TFBS), duration of hospital stay (DHS), and postoperative complication rate (PCR).
Results: A total of 114 patients were included, with 38 patients allocated to each group. TFF was significantly shorter in the CDG (25.8 h vs. 38.1 h, P < 0.001) and the HDG (23.1 h vs. 38.1 h, P < 0.001) than the PCG. TFBS was significantly reduced in the CDG (16.1 h vs. 19.3 h, P < 0.05) and the HDG (14.3 h vs. 19.3 h, P < 0.001). Patients in the HDG had a significantly shorter TFD than the PCG (61.2 h vs. 66.4 h, P < 0.05). However, DHS did not differ significantly among the groups. PCR was markedly lower in the CDG (34.2% vs. 68.4%, P < 0.01) and HDG (21.1% vs. 68.4%, P < 0.001) compared to the PCG. No adverse events were reported across the groups.
Conclusion: Bacillus coagulans TBC169 accelerates intestinal function recovery and reduces postoperative complications following gynecologic open surgery.
Trial registration: The study protocol was registered with the China Clinical Trials Registry (ChiCTR2200059518).
期刊介绍：
The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences.
IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy.
IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor.
International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy .
Until 2010 the journal was called Pharmacy World & Science.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
